市場調査レポート

商品コード

1766592

軸性脊椎関節炎市場：タイプ別、治療薬別、投与経路別、製品タイプ別、性別、流通チャネル別、エンドユーザー別、地域別

Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography

出版日: 2025年06月27日
発行: Coherent Market Insights
ページ情報: 英文 165 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,500 664,470円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,033,620円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,476,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.66円

全表示
概要
目次

概要

サンプル依頼リストに入れる

軸性脊椎関節炎市場は、2025年に44億1,000万米ドルと推定され、2032年には70億1,000万米ドルに達すると予測され、2025年から2032年までのCAGRは6.85%で成長すると予測されます。

レポート範囲		レポート詳細
基準年	2024	2025年の市場規模	44億1,000万米ドル
実績データ	2020年から2024年まで	予測期間	2025年から2032年
予測期間：2025年～2032年CAGR：	6.85%	2032年の価値予測	70億1,000万米ドル

軸性脊椎関節炎（axSpA）は、主に脊椎と仙腸関節に影響を及ぼす慢性炎症性リウマチ性疾患であり、進行性の構造的損傷、機能障害、患者のQOLへの重大な影響を特徴とします。世界の軸性脊椎関節炎市場は、世界中で数百万人が罹患しているこの衰弱状態に対処するために設計された治療介入、診断ツール、管理ソリューションの包括的なスペクトルを包含しています。この市場には、X線撮影型の強直性脊椎炎（AS）と、非X線撮影型の腋窩脊椎関節炎（nr-axSpA）の両方が含まれ、疾患の分類と進行に関する理解の進展を反映しています。ヘルスケア専門家や患者の意識の高まりに加え、早期診断や標的生物学的製剤の進歩により、同市場は大幅な成長の勢いを見せています。

腫瘍壊死因子（TNF）阻害剤、インターロイキン-17（IL-17）阻害剤、新興のヤヌスキナーゼ（JAK）阻害剤などが治療の主流を占めており、患者に症状管理の改善と疾患改善の可能性を提供しています。ヘルスケア支出の増加、自己免疫疾患の有病率の増加、高度な画像診断技術による診断能力の向上、強力な医薬品の研究開発活動が総体的に市場拡大を後押ししており、世界の軸性脊椎関節炎市場は、より広範なリウマチ治療薬業界の中で重要なセグメントとして位置付けられています。

市場力学

軸性脊椎関節炎の世界市場は、市場成長の見通しと治療進歩の機会を高めるいくつかの強力な促進要因に後押しされています。特に20～40歳の若年層における疾患有病率の増加は、世界人口の0.7%がaxSpAに罹患していると推定されることから、効果的な治療ソリューションに対する大きな需要を生み出し、成長の主要な触媒となっています。磁気共鳴画像法（MRI）や特殊なバイオマーカーを含む高度な画像診断技術による認知度の向上と診断能力の向上により、疾患の早期発見と介入が可能となり、治療可能な患者集団が大幅に拡大します。革新的な生物学的製剤と標的化合成疾患修飾性抗リウマチ薬（tsDMARDs）の強力なパイプラインは、治療効果の向上と個別化された治療アプローチを提供し、割高な価格設定と患者転帰の改善を通じて市場拡大を牽引しています。

しかし、生物学的製剤の治療費は患者1人当たり年間5万米ドルを超えることもあり、価格に敏感な市場での利用が制限されるとともに、世界のヘルスケアシステムに償還の課題をもたらすなど、市場成長は顕著な抑制要因に直面しています。新規治療薬の厳しい承認プロセスは、大規模な臨床試験要件と相まって、開発期間の長期化と開発コストの増大を招き、新興治療薬の市場参入を阻害する可能性があります。さらに、axSpAの診断は複雑であり、しばしば誤診や診断の遅れが生じるため、タイムリーな治療開始や市場浸透の障壁となっています。とはいえ、新興経済諸国における医療インフラの拡大、医療支出の増加、ブランド生物製剤の代替となる費用対効果の高いバイオシミラー医薬品の受け入れ拡大により、先進治療へのアクセスが民主化され、多様な地域や経済セグメントにまたがる市場の拡大が期待されることから、大きなビジネスチャンスが生まれています。

本調査の主な特徴

本レポートでは、世界の腋窩脊椎関節炎市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）および複合年間成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の軸性脊椎関節炎市場の主要企業プロファイルを掲載しています。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関して、情報に基づいた意思決定を行うことができます。
この調査レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
利害関係者は、世界の軸性脊椎関節炎市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 4.41 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.85%	2032 Value Projection:	USD 7.01 Bn

Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.

The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.

Market Dynamics

The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.

However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.

Key Features of the Study

This report provides in-depth analysis of the global axial spondyloarthritis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global axial spondyloarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
Therapeutics Insights (Revenue, USD Bn, 2020 - 2032)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- Conventional DMARDs
- Sulfasalazine
- Methotrexate
- Others (Corticosteroids, etc.)
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Subcutaneous (SC) Injections
- Intravenous (IV) Infusions
Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Female
- Male
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Rehabilitation & physiotherapy centers
- Others (Academic and Research Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Axial Spondyloarthritis Market, By Type
- Global Axial Spondyloarthritis Market, By Therapeutics
- Global Axial Spondyloarthritis Market, By Route of Administration
- Global Axial Spondyloarthritis Market, By Product Type
- Global Axial Spondyloarthritis Market, By Gender
- Global Axial Spondyloarthritis Market, By Distribution Channel
- Global Axial Spondyloarthritis Market, By End User
- Global Axial Spondyloarthritis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Non-radiographic Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Meloxicam
    - Naproxen
    - Celecoxib
    - Diclofenac
    - Others (Indomethacin, etc.)
Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - TNF inhibitors
    - Adalimumab
    - Infliximab
    - Etanercept
    - Others (Golimumab, etc.)
    - IL-17 inhibitors
    - Secukinumab
    - Ixekizumab
    - Others (Bimekizumab, etc.)
    - JAK inhibitors
    - Tofacitinib
    - Upadacitinib
Conventional DMARDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Sulfasalazine
    - Methotrexate
Others (Corticosteroids, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous (SC) Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravenous (IV) Infusions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rehabilitation & physiotherapy centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

13. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

14. References and Research Methodology

References
Research Methodology
About us

軸性脊椎関節炎市場：タイプ別、治療薬別、投与経路別、製品タイプ別、性別、流通チャネル別、エンドユーザー別、地域別

Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography

市場力学

目次

第1章調査の目的と前提条件

第2章市場の展望

第3章市場力学、規制、動向分析

第4章世界の軸性脊椎関節炎市場、タイプ別、2020年～2032年

第5章世界の軸性脊椎関節炎市場、治療薬別、2020年～2032年

第6章世界の軸性脊椎関節炎市場、投与経路別、2020年～2032年

第7章世界の軸性脊椎関節炎市場、製品タイプ別、2020年～2032年

第8章世界の軸性脊椎関節炎市場、性別、2020年～2032年

第9章世界の軸性脊椎関節炎市場、流通チャネル別、2020年～2032年

第10章世界の軸性脊椎関節炎市場、エンドユーザー別、2020年～2032年

第11章世界の軸性脊椎関節炎市場、地域別、2020年～2032年

第12章競合情勢

第13章アナリストの推奨事項

第14章参考文献と調査手法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)

5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)

6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)

7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)

8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)

9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)

10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)

11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)

12. Competitive Landscape

13. Analyst Recommendations

14. References and Research Methodology

軸性脊椎関節炎市場：タイプ別、治療薬別、投与経路別、製品タイプ別、性別、流通チャネル別、エンドユーザー別、地域別

Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography

市場力学

目次

第1章 調査の目的と前提条件

第2章 市場の展望

第3章 市場力学、規制、動向分析

第4章 世界の軸性脊椎関節炎市場、タイプ別、2020年～2032年

第5章 世界の軸性脊椎関節炎市場、治療薬別、2020年～2032年

第6章 世界の軸性脊椎関節炎市場、投与経路別、2020年～2032年

第7章 世界の軸性脊椎関節炎市場、製品タイプ別、2020年～2032年

第8章 世界の軸性脊椎関節炎市場、性別、2020年～2032年

第9章 世界の軸性脊椎関節炎市場、流通チャネル別、2020年～2032年

第10章 世界の軸性脊椎関節炎市場、エンドユーザー別、2020年～2032年

第11章 世界の軸性脊椎関節炎市場、地域別、2020年～2032年

第12章 競合情勢

第13章 アナリストの推奨事項

第14章 参考文献と調査手法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)

5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)

6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)

7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)

8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)

9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)

10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)

11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)

12. Competitive Landscape

13. Analyst Recommendations

14. References and Research Methodology

第1章調査の目的と前提条件

第2章市場の展望

第3章市場力学、規制、動向分析

第4章世界の軸性脊椎関節炎市場、タイプ別、2020年～2032年

第5章世界の軸性脊椎関節炎市場、治療薬別、2020年～2032年

第6章世界の軸性脊椎関節炎市場、投与経路別、2020年～2032年

第7章世界の軸性脊椎関節炎市場、製品タイプ別、2020年～2032年

第8章世界の軸性脊椎関節炎市場、性別、2020年～2032年

第9章世界の軸性脊椎関節炎市場、流通チャネル別、2020年～2032年

第10章世界の軸性脊椎関節炎市場、エンドユーザー別、2020年～2032年

第11章世界の軸性脊椎関節炎市場、地域別、2020年～2032年

第12章競合情勢

第13章アナリストの推奨事項

第14章参考文献と調査手法